Dynavax Technologies Corp. and partner Merck & Co. Inc. said their Phase III trial of hepatitis B vaccine Heplisav met its primary endpoint of inducing a noninferior antibody response compared to GlaxoSmithKline plc's marketed hepatitis B vaccine, Engerix-B. (BioWorld Today) Read More
